Together, we'll explore these aspects in detail
GLP1R carries an Open Targets CVD association score of 0.35
Beyond Basal Insulin When treatment is intensified beyond basal insulin therapy, a number of factors should be taken into account as part of the shared decision-making process, such as patient preference, safety, tolerability, glycemic efficacy, risk of hypoglycemia, and other non-glycemic effects (e.g., weight change and/or impact on life-style) [13]
Therefore, we sought a less-sensitive functional assay with reduced receptor expression levels to enable the optimization of efficacy-driven GLP-1R agonists for clinical development
Medical nutrition therapy and other approaches to management of post-bariatric hypoglycemia: a team-based approach